Tnf α dta00d

Serum levels of IDO and cytokines (TNF-α, IL-1β, IFN-γ, IL-4, IL-6, IL-17) were determined at baseline and at 6 weeks of follow-up. Venous blood was collected from the forearm between 6 and 7 a.m. following an overnight fast. Serum levels of IDO and six cytokines were measured by quantitative enzyme-linked immunosorbent assay (ELISA) using a commercially available kit: IDO (SEB547Hu, sensitivity: minimum detectable measurement ≤ 0.118 ng/mL) (Cloud-Clone, Wuhan, China), IFN-γ (SEA049Hu, sensitivity: minimum detectable measurement ≤ 6.1 pg/ml) (Cloud-Clone, Wuhan, China), IL-4 (SEA077Hu, sensitivity: minimum detectable measurement≤5.9 pg/ml) (Cloud-Clone, Wuhan, China), IL-6 (SEA079Hu, sensitivity: minimum detectable measurement ≤ 3.2 pg/ml) (Cloud-Clone, Wuhan, China), and IL-17 (SEA063Hu, sensitivity: 5.5 pg/ml) (Cloud-Clone, Wuhan, China), TNF-α (DTA00D, sensitivity: 6.23 pg/ml) (R&D Systems, USA), IL-1β (DLB50, sensitivity: 1 pg/ml) (R&D Systems, USA). All ELISA kits used in this study have been cross-reactivity validation of existing related factors to ensure their specificity. All assays were blinded to group or behavior information until after the results were finalized.

Fasting cubital venous blood (5 mL) of all patients were collected within 24 hours after admission. The blood samples were collected in tubes containing EDTA and were centrifuged at 2000 g for 15 minutes. The enzyme-linked immunosorbent assay (ELISA) method was used for measurement of serum SIRT3, interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α using commercially available ELISA kits (SIRT3, MBS2022533 MYBio; IL-1β DLB50 R&D Systems; IL-6 MBS175877 MYBio; TNF-α DTA00D R&D Systems).